Levetiracetam Ibigen (Levetiracetam)

Levetiracetam binds to the synaptic vesicle protein SV2A, which modulates neurotransmitter release. This action stabilises neuronal membranes, lowers neuronal excitability, and limits the spread of abnormal electrical activity that triggers seizures, providing broad‑spectrum seizure control.

The dosage of Levetiracetam Ibigen is determined by the prescribing clinician based on the patient’s age, weight, renal function, and clinical response. Healthcare professionals set the appropriate dose and infusion rate for each individual case.

The safety of levetiracetam in pregnancy and lactation has not been fully established. Physicians should evaluate the potential benefits against possible risks and discuss alternative options when treating pregnant or nursing patients.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain if needed) and necessary import documentation.

Levetiracetam offers a distinct mechanism by targeting SV2A, which differs from sodium‑channel blockers like carbamazepine or GABA‑enhancers such as valproate. It is generally well tolerated, has fewer drug‑enzyme interactions, and can be administered intravenously, making it useful for acute seizure control or when oral therapy is not feasible.

Levetiracetam Ibigen should be stored below 25 °C in its original container, protected from moisture and direct light. Do not freeze the solution. Before administration, inspect for particulate matter and ensure the product is at room temperature.

Levetiracetam Ibigen is given intravenously by slow infusion under the supervision of qualified healthcare personnel. The infusion rate and total daily dose are prescribed by the treating physician, and the solution should be administered using aseptic technique.

Serious risks include severe allergic reactions such as anaphylaxis, skin conditions like Stevens‑Johnson syndrome, blood disorders (e.g., neutropenia), and neuropsychiatric events such as suicidal thoughts or severe depression. Prompt medical attention is required if any of these occur.

Patients with known hypersensitivity to levetiracetam or any component of the formulation should avoid its use. Caution is also advised for individuals with severe renal impairment, uncontrolled psychiatric disorders, or those taking interacting medications that may significantly alter levetiracetam levels.